Whooping cough vaccines composition, tolerance, immunogenicity and efficacity. Justification of the vaccine calendar in France;Les vaccins coquelucheux composition, tolérance, immunogénicité et efficacité. Justifications du calendrier vaccinal en France

Medecine et Maladies Infectieuses

Volumn 31, Issue SUPPL. 1, 2001, Pages 86-97

  Gaudelus, J ^a   Guiso, N ^b   Reinert, P ^c  

^a HÔPITAL JEAN VERDIER   (France)

^b INSTITUT PASTEUR   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Tolerance; Whooping cough vaccines

Indexed keywords

BACTERIAL PROTEIN; BIKEN2; DTCA1; DTCA2; DTCA2 PMSV; DTCA3; DTCA4; DTCA5; DTCE; DTCE PMSV; PERTUSSIS VACCINE;

BORDETELLA PERTUSSIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FRANCE; HUMAN; IMMUNOGENICITY; PERTUSSIS; SUSPENSION; VACCINATION;

EID: 0035069941     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(01)00174-3     Document Type: Conference Paper

References (62)

1. Evolutionary relationships in the genus Bordetella
2. General considerations concerning pertussis, with special emphasis on vaccine therapy - Prophylatic and curative
3. Vaccination against whooping cough
4. Protective antigen of Haemophilus pertussis
5. Pertussis immunization program of the Boston Health Department. The comparative value of two different antigens
6. Extracted pertussis antigen. A clinical appraisal
7. The epidemiological evaluation of a non cellular pertussis antigen
8. Mouse protection tests in the study of pertussis vaccine
9. Vaccination against whooping cough. Relation between protection in children and results of laboratory test
10. Vaccination against whooping cough
11. Sero-specific protection of mice against intranasal infection with Bordetella pertussis
12. Type-specific immunity vaccine, a little cuse for concern
13. Bordetella pertussis whole-cell vaccine. Efficacy and toxicity
14. Enquête: Absence de liaison entre la vaccination tétravalente et le syndrome de mort subite du nourrisson
15. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine
16. Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. A population -based case-control study
17. History of convulsions and use of pertussis vaccine
18. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children
19. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine
20. Epidemiology of pertussis
21. Western blot analysis of antibody responses of young infants to pertussis infection
22. Acellular and whole-cell pertussis vaccines as booster doses: A multicenter study
23. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France
24. Comparison of pertussis antibody levels in children up to 5 years of age primed at 2, 3, 4 months and boostered in the second year of life with either DTPa or DTPw based combination vaccines, in France
25. Cell-mediated immunity (CMI) in children 2.5 to 5 years of age 1-3 years after vaccination with either DTPa or DTPw based combination vaccines in France
26. Dissecting human T cell responses against Bordetella species
27. Human T cell clones define Sl subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map
28. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity
29. Identification of human T-cell epitopes on the S4 subunit of pertussis toxin
30. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine
31. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis
32. Epidemiology of pertussis in French hospitals in 1993 and 1994 thirty years after a routine use of vaccination
33. Renacoq surveillance de la coqueluche à l'Ho̧pital en 1998. Brian de 3 années de surveillance
34. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines
35. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal
36. Current epidemiology of pertussis in Japan
37. Comparison of 13 acellular pertussis vaccines adverse reactions
38. Comparison of DRaP-IPV and DT polio vaccines as a second booster at 8 to 12 years
39. Cellular immunity in pertussis
40. Cell-mediated immunity to Bordetella pertussis : Role of Th1 cells in bacterial clearance in a murine respiratory infection model
41. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen : Adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28
42. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine
43. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines
44. Intranasal murine model of Bordetella pertussis infection : II. Sequence variation and protection induced by a tricomponent acellular vaccine
45. Information - Calendrier vaccinal
46. The return of pertussis
47. Return of epidemic pertussis in the United States
48. La coqueluche en France
49. La coqueluche en France : Nécessité de la mise en place d'une surveillance
50. New aspects of pertussis in France, 26 years after generalized pertussis vaccination
51. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure
52. Efficacy of acellular pertussis vaccine in early childhood after household exposure
53. Randomised controlled trial of two-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc group for the study of pertussis vaccine
54. Immunogenicity and reactogenicity of a booster dose of diphteria, tetanus, acellular pertussis and inactivated poliomyelitis vaccines given concurrently with Haemophilus type b conjugate vaccine or as pentavalent vaccine
55. Comparative reactogenicity and immunogenicity of booster doses of diphteria-tetanus-acellular-inactivated poliovirus vaccine and diphteria-tetanus-inactivated poliovirus vaccine in pre-adolescents
56. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines
57. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden
58. Still more questions on pertussis vaccines
59. Analysis of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis combination vaccines
60. A placebo-controlled trial of a pertussis-toxoid vaccine
61. Efficacy of a two-component acellular pertussis vaccine in infants